A Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment

This is an open-label pharmacokinetic study of TS-142 in patients with hepatic impairment

Inclusion Criteria:<Inclusion criteria for patients with hepatic impairment>Japanese male and female who are aged 18 to 75 years at the time of informed consentPatients with cirrhosisPatients classified as Child-Pugh classification A (mild) or B (moderate) by the principal investigator or sub-investigator at the screening test Other protocol defined inclusion criteria could apply.<Inclusion criteria for subject with normal hepatic function>Japanese male and female who are aged 18 to 75 years at the time of informed consentBody Mass Index (BMI) between 18.5 and 35.0 at the screening test Other protocol defined inclusion criteria could apply.Exclusion Criteria:<Exclusion criteria for patients with hepatic impairment>Patients who have a history of liver resection or liver transplantPatients with hepatic encephalopathy of grade II or higherPatients with epidermal growth factor receptor (eGFR) less than 45 mL/min/1.73 m2 at the screening test Other protocol defined exclusion criteria could apply.<Exclusion criteria for subjects with normal hepatic function>Subjects who are judged to have any disease by the principal investigator or sub-investigatorSubjects with eGFR less than 60 mL/min/1.73 m2 at the screening test Other protocol defined exclusion criteria could apply.